BioInvent Q2 2023: Progress on all Fronts - Redeye

Since our last update, new readouts have been published with BI-1808 and BI-1206 in solid tumours. We review these results and the near-term outlook of the project portfolio. In particular, we expect news about the subcutaneous version of BI-1206 soon, which will be key to its future development.

Länk till analysen i sin helhet: https://www.redeye.se/research/940560/bioinvent-q2-2023-progress-on-all-fronts?utm_source=finwire&utm_medium=RSS